Side Effects of selexipag: A Synthesis of Findings from 13 Studies

  1. Home
  2. Side Effects of selexipag
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of selexipag: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of selexipag: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Selexipag is an oral medication used to treat pulmonary arterial hypertension (PAH), a condition where the blood pressure in the arteries of the lungs is abnormally high. 13 It works by activating a specific type of receptor in the body called the prostacyclin (IP) receptor. This activation helps relax the blood vessels in the lungs, reducing blood pressure and improving blood flow. 13

One of the key advantages of selexipag is its high selectivity for the IP receptor. This means that it primarily acts on the IP receptor and not other similar receptors in the body, reducing the potential for side effects. 11 In fact, studies have shown that selexipag does not significantly affect gastric function, unlike some other medications that activate the prostacyclin pathway. 11

Selexipag also has a unique property in that it does not cause a paradoxical vasoconstriction (narrowing of blood vessels) in the legs, which is a common side effect of other prostacyclin analogs. 1 This makes selexipag a potentially safer option for patients with PAH who experience leg pain or discomfort. 1

Reasons for Side Effects

While selexipag is generally well-tolerated, it can still cause some side effects. These side effects are typically related to its mechanism of action as a prostacyclin receptor agonist and can include headache, nausea, jaw pain, and diarrhea. 2 These side effects are similar to those seen with other prostacyclin analogs but are generally less severe with selexipag due to its high selectivity for the IP receptor. 2

Common Side Effects

Headache

Headache is the most commonly reported side effect of selexipag. 2

Nausea

Nausea is another common side effect associated with selexipag treatment. 2

Jaw Pain

Jaw pain has also been reported as a side effect of selexipag. 2

Diarrhea

Diarrhea is a less common side effect of selexipag but can occur in some patients. 2

Measures for Side Effects

Measures for Headache

If you experience a headache, consult your doctor. They may recommend over-the-counter pain relievers or other treatments to manage the headache. 2

Measures for Nausea

If you experience nausea, try eating small, frequent meals. You can also consult your doctor about anti-nausea medication. 2

Measures for Jaw Pain

If you experience jaw pain, consult your doctor to determine the cause and receive appropriate treatment. 2

Measures for Diarrhea

If you experience diarrhea, stay hydrated by drinking plenty of fluids. You can also consult your doctor about antidiarrheal medication. 2

Comparison of Studies

Commonalities of Studies

Multiple studies have shown that selexipag is effective in treating PAH. 13 6 It has also been demonstrated to be generally safe and well-tolerated. 2 3 Additionally, selexipag has shown a distinct advantage over other prostacyclin analogs in terms of its selectivity for the IP receptor, potentially leading to fewer side effects. 11 1

Differences in Studies

The frequency and severity of side effects reported in different studies can vary. 2 This variation might be due to differences in study design, patient populations, and other factors. 2

Points to Note Regarding Application in Real Life

While selexipag is a promising treatment option for PAH, it's important to remember that it can cause side effects. 2 If you are considering selexipag treatment, talk to your doctor about the potential risks and benefits. 2

Limitations of Current Research

There is still limited research on the long-term safety and efficacy of selexipag. 2 Further research is also needed to assess its effectiveness in high-risk PAH patients and children. 10 7

Future Research Directions

Future research should focus on gathering more data on the long-term safety and efficacy of selexipag. 2 Research is also needed to evaluate selexipag's effectiveness and safety in high-risk PAH patients and children. 10 7

Conclusion

Selexipag is a promising treatment option for PAH, but it's important to be aware of its potential side effects. 2 If you are considering selexipag treatment, discuss the risks and benefits with your doctor and ask any questions you may have. 2

Literature analysis of 13 papers
Positive Content
12
Neutral Content
0
Negative Content
1
Article Type
1
0
1
2
11
2.

Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.

Author: BrudererShirin, HurstNoémie, RemenovaTatiana, DingemanseJasper

Pulmonary arterial hypertension treatment
Diarrhea
Headache
Jaw pain
Nausea

Selexipag is the first oral, non-prostanoid, selective prostacyclin receptor agonist approved for the long-term treatment of pulmonary arterial hypertension (PAH) in adults. A clinical trial showed that selexipag significantly reduced the risk of morbidity/mortality in PAH patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies.

Author: NelsonErik J, CookElla, NelsonSamara, BrownRebecca, PierceMegan, SeelosAshley Bangerter, StickleHeather, JohansenMichael

Family burden
Side effects

Pulmonary hypertension (PH) is a serious condition in children, but treatment therapies are often used "off label". This study aims to understand the side effect profiles of commonly used pediatric PH therapies and the burdens faced by families caring for children with PH.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension.

Author: RothmanAbraham, CruzGabriel, EvansWilliam N, RestrepoHumberto

PAH treatment

Selexipag, an oral prostacyclin receptor agonist, was safe and well-tolerated in four pediatric patients with pulmonary hypertension over 16-28 months. One patient successfully transitioned from subcutaneous treprostinil to selexipag.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series.

Author: LemmersJacqueline Mj, FretheimHåvard, KnaapenHanneke Ka, van den HoogenFrank Hj, van Haren-WillemsJolanda Hgm, DuijnhouwerAnthony L, van DijkArie P, van den EndeCornelia Hm, Hoffmann-VoldAnna-Maria, VonkMadelon C

Symptom stabilization
Side effects

Selexipag provided sustained stabilization of symptoms in patients with systemic sclerosis-associated pulmonary arterial hypertension. Improvement was observed in only two patients. Further research is needed.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

9.

Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.

Author: CuiXiaopei, LuWeida, ZhangDeyuan, QieLiangyi, LiHaijun, LiXiao, LiuHui, JiQiushang

Efficacy
Safety

Selexipag is an oral prostacyclin receptor agonist for pulmonary arterial hypertension (PAH). This study assesses the safety and efficacy of selexipag in triple combination therapy for Chinese PAH patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report.

Author: RossiSerena, PietrangeloCarla, PierdomenicoSante Donato, GiulianiLivio

Improved PAH symptoms

Off-label triple oral combination therapy including a phosphodiesterase-5 inhibitor, an endothelin receptor antagonist, and selexipag may be a viable alternative to parenteral prostacyclin analogues (PCAs) in patients with high-risk pulmonary arterial hypertension (PAH).

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

12.

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Author: SitbonOlivier, ChannickRichard, ChinKelly M, FreyAline, GaineSean, GalièNazzareno, GhofraniHossein-Ardeschir, HoeperMarius M, LangIrene M, PreissRalph, RubinLewis J, Di ScalaLilla, TapsonVictor, AdzerikhoIgor, LiuJinming, MoiseevaOlga, ZengXiaofeng, SimonneauGérald, McLaughlinVallerie V,

Reduced risk of complications
Reduced risk of death
Diarrhea
Headache
Jaw pain
Nausea

Selexipag was found to be effective in reducing the risk of death or a complication related to pulmonary arterial hypertension in patients with pulmonary arterial hypertension.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Selexipag for the treatment of pulmonary arterial hypertension.

Author: Skoro-SajerNika, LangIrene Marthe

PAH treatment

Selexipag is a first-in-class orally available selective non-prostanoid IP receptor agonist that is being evaluated in a Phase III trial for the treatment of pulmonary arterial hypertension (PAH). Selexipag has the potential to offer a convenient first-line prostacyclin treatment option for patients with PAH.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.